Eisai | Jotup

UsAgainstAlzheimer’s Launches 2024 Brain Health Academy

Retrieved on:

Dienstag, April 16, 2024

Brain, Nutrition, Risk, Dietitian, Eisai, Doctor, Dementia, Growth, Tivity Health, Ageing, Patient, Society, AARP, American Heart Association

Each of the hour-long virtual sessions will be recorded and available for on-demand viewing up to 60 days after the live presentation.

Key Points:

Each of the hour-long virtual sessions will be recorded and available for on-demand viewing up to 60 days after the live presentation.
A testament to the Academy’s impact, more than 5,300 individuals benefitted from the free, evidence-based education program.
More than half of participants reported a significant shift in their approach to brain health and how they discuss risk factors and dementia with their patients.
“With educational programs like the Brain Health Academy, we can empower health care professionals to better serve those whom they serve by counseling them about the importance of promoting and protecting their brain health and reducing their risk of developing brain disease.”
The Brain Health Academy is made possible through its collaborative efforts with partners, including the Academy of Doctors of Audiology, Academy of Nutrition and Dietetics, American Society on Aging, AARP, American Academy of Sleep Medicine, American Heart Association, American College of Lifestyle Medicine, Centers for Disease Control and Prevention, Eisai, Humana, Physical Activity Alliance, Tivity Health, and USAging.

Mission Based Media Presents 'Rethinking Alzheimer's Disease,' a New Health UNMUTED Podcast Series

Retrieved on:

Freitag, April 12, 2024

Alzheimer's disease, Education, American Academy, Hope, Eisai, Research, Mission, Neurology, Patient, AAN, Caregiver, Disease, Diagnosis, Amnesia, Medical imaging

DENVER, April 12, 2024 /PRNewswire/ -- Mission Based Media, an integrated digital media and health content company specializing in podcasts, today announced the release of Rethinking Alzheimer's Disease, a new addition to the innovative Health UNMUTED® platform.

Key Points:

DENVER, April 12, 2024 /PRNewswire/ -- Mission Based Media, an integrated digital media and health content company specializing in podcasts, today announced the release of Rethinking Alzheimer's Disease, a new addition to the innovative Health UNMUTED® platform.
Rethinking Alzheimer's Disease provides insights and information about the prevention and diagnosis of Alzheimer's disease.
The Rethinking Alzheimer's Disease podcast explains how Alzheimer's develops, and how early detection can provide individuals with more treatment options and valuable time to plan for the future.
"When most people think of Alzheimer's disease, they think of memory loss and getting older," said Dan Kendall, founder of Mission Based Media and executive producer of Health UNMUTED.

Immuta Recognized as a Top Company on Forbes' Annual List of America's Best Startup Employers

Retrieved on:

Donnerstag, April 11, 2024

BOSTON, April 11, 2024 /PRNewswire/ -- Immuta, a leader in data security, has been named one of the top companies on Forbes' annual list of America's Best Startup Employers for the fourth consecutive year. The list, developed in partnership with market research company Statista, was compiled by evaluating 3,000 U.S. businesses with at least 50 employees on three criteria: employer reputation, employee satisfaction, and growth. It recognizes the top startups that show exemplary focus on these three areas, fostering strong company culture and employee happiness.

Key Points:

Immuta is again recognized as one of America's top 500 startups for employee satisfaction, reputation, and growth
BOSTON, April 11, 2024 /PRNewswire/ -- Immuta , a leader in data security, has been named one of the top companies on Forbes' annual list of America's Best Startup Employers for the fourth consecutive year.
It recognizes the top startups that show exemplary focus on these three areas, fostering strong company culture and employee happiness.
The recognition follows an impressive year of innovation and momentum for Immuta and its data security offering.
Product Growth and Expansion – Launched Immuta Discover for tagging, classification, and managing highly accurate metadata for the purpose of data access control.

Orsini Announcement: Orsini Specialty Pharmacy Welcomes Two Executive Leadership Hires

Retrieved on:

Donnerstag, April 4, 2024

Haddock, Growth, CFO, Eisai, Patient, ELK, Pharmacy, University, Senior, Express Scripts, IQVIA, Economics, Management

ELK GROVE VILLAGE, III., April 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy is pleased to announce that it has welcomed Victor Haddock as its new Chief Financial Officer and Lynda Parker as Executive Vice President of Trade Relations and Account Management.

Key Points:

ELK GROVE VILLAGE, III., April 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy is pleased to announce that it has welcomed Victor Haddock as its new Chief Financial Officer and Lynda Parker as Executive Vice President of Trade Relations and Account Management.
Orsini Specialty Pharmacy welcomes Victor Haddock and Lynda Parker to Executive Leadership Team.
Haddock has over 25 years of financial leadership experience in the healthcare sector, with a demonstrated ability to lead business strategies, implement change and build successful teams.
He most recently served as CFO of Triple-S Management in Puerto Rico, and he has held leadership positions at MagellanRx and Express Scripts.

BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease

Retrieved on:

Dienstag, März 19, 2024

Diagnosis, Amyloid, Brain, Disease, Eisai, Patient, Research, European Grand Prix

"Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me throughout my research life," said Professor Lars Lannfelt.

Key Points:

"Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me throughout my research life," said Professor Lars Lannfelt.
Professor Lars Lannfelt founded BioArctic together with Pär Gellerfors in 2003 to develop an antibody treatment based on Lannfelt's groundbreaking discoveries of the role of amyloid-beta protein in Alzheimer's disease.
By binding to specific forms of amyloid-beta, which causes Alzheimer's disease, lecanemab helps to clear them from the brain, thereby altering the course of the disease.
La Fondation Recherche Alzheimer was founded in 2004 and aims to improve the diagnosis of Alzheimer's disease and pave the way for effective treatments.

BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease

Retrieved on:

Dienstag, März 19, 2024

Diagnosis, Amyloid, Brain, Disease, Eisai, Patient, Research, European Grand Prix

"Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me throughout my research life," said Professor Lars Lannfelt.

Key Points:

"Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me throughout my research life," said Professor Lars Lannfelt.
Professor Lars Lannfelt founded BioArctic together with Pär Gellerfors in 2003 to develop an antibody treatment based on Lannfelt's groundbreaking discoveries of the role of amyloid-beta protein in Alzheimer's disease.
By binding to specific forms of amyloid-beta, which causes Alzheimer's disease, lecanemab helps to clear them from the brain, thereby altering the course of the disease.
La Fondation Recherche Alzheimer was founded in 2004 and aims to improve the diagnosis of Alzheimer's disease and pave the way for effective treatments.

BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress

Retrieved on:

Montag, März 11, 2024

Diagnosis, Brain, Conference, Lecanemab, Disease, Incidence, Alpha-synuclein, Eisai, Patient, CAA, ARIA, DSM-IV codes, Antibody, Safety, Clarity, Pharmaceutical industry

BioArctic's founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta (Aβ) antibody lecanemab and other anti Aβ antibodies.

Key Points:

BioArctic's founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta (Aβ) antibody lecanemab and other anti Aβ antibodies.
Lecanemab was designed to preferentially bind soluble (protofibrils), as well as insoluble Aβ aggregates (fibrils), to reduce both Aβ protofibrils and Aβ plaques in the brain.
The difference in binding to CAA[1] was presented, with lecanemab having lower binding to CAA than most other antibodies.
This could explain the difference in the adverse event ARIA[2] seen between different antibodies, with lecanemab showing relatively low incidence of ARIA.

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Retrieved on:

Montag, März 4, 2024

OGA, Research, BIIB, Investment, Eisai, Alpha-synuclein, Amyloid, Conference, Biogen, Quantitative systems pharmacology, Dementia, MCI, QSP, Clarity, MAPT, Brain, Vaccine

The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.

Key Points:

The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.
In addition to BIIB113, Biogen is researching the potential of tau reduction in AD with its investigational antisense oligonucleotide targeting the microtubule associated protein tau (MAPT) gene (BIIB080).
Oral presentation: Results of the first in-human, randomized, blinded, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
Oral presentation: Lecanemab for the treatment of early Alzheimer’s disease; the extension of efficacy results from Clarity AD.

C₂N Diagnostics, LLC Announces Investment From Eisai Inc.

Retrieved on:

Mittwoch, März 6, 2024

Biotechnology, Neurology, Health, Pharmaceutical, Health Technology, Senior, Pathology, Eisai, Growth, Deficit spending, History, Patient, Dementia, CSF, Diagnosis, PET, Medical imaging

C₂N Diagnostics, LLC , a leader in advanced brain health diagnostics, and Eisai Inc. , a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.

Key Points:

C₂N Diagnostics, LLC , a leader in advanced brain health diagnostics, and Eisai Inc. , a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.
C₂N executives say the investment reflects the two companies’ shared desire to scale up and provide broad access to its Precivity™ tests , which are innovative blood tests intended for use in patients with cognitive impairment.
These tests aim to help healthcare providers determine Alzheimer’s disease pathology, and aid in medical management and treatment decisions.
“Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem’s growth.

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

Dienstag, Februar 27, 2024

Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.

Key Points:

Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.
Costs of Captisol sales were $1.6 million for the fourth quarter of 2023, compared with $21.6 million for the same period in 2022, with the decrease due to lower total Captisol sales during the fourth quarter of 2023 and $9.8 million in accelerated depreciation on Captisol manufacturing equipment during the fourth quarter of 2022.
Amortization of intangibles was $8.3 million for the fourth quarter of 2023, compared with $8.5 million for the same period in 2022.
Travere also announced fourth quarter 2023 results reporting that it received 459 new patient start forms for FILSPARI in the fourth quarter of 2023 and net product sales of $14.9 million for the fourth quarter.